Yahoo
NasdaqGM - Delayed Quote USD

Nyxoah SA (NYXH)

0.8456 +0.0346 (+4.27%)
At close: November 6 at 4:00:01 PM EST
Trade Nyxoah on Coinbase
NYXH Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for NYXH
  • Previous Close 0.8110
  • Open 0.8300
  • Bid 1.4400 x 100
  • Ask 1.4100 x 100
  • Day's Range 0.8001 - 0.8543
  • 52 Week Range 0.8000 - 5.9200
  • Volume 262,087
  • Avg. Volume 313,770
  • Market Cap (intraday) 86.116M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -2.5600
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 2.78
  • Zacks Rating Neutral

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

www.nyxoah.com

153

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is BEL 20 (^BFX) .

YTD Return

NYXH
81.82%
BEL 20 (^BFX)
18.09%

1-Year Return

NYXH
83.05%
BEL 20 (^BFX)
22.39%

3-Year Return

NYXH
85.32%
BEL 20 (^BFX)
71.14%

5-Year Return

NYXH
96.48%
BEL 20 (^BFX)
36.72%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 9.17M
Earnings -17.83M
Profit Margin -194.44%

Q3

FY25

Q4

FY25

Q2

FY26

Q3

FY26

-30M
-20M
-10M
0
-1000.0%
-800.0%
-600.0%
-400.0%
-200.0%

Analyst Insights

View More

Analyst Price Targets

1.49
2.78 Average
0.8456 Current
3.87 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst Cantor Fitzgerald
Rating Action Maintains
Rating Overweight
Price Action Lowers
Price Target 6 -> 3

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.06%

  • Return on Equity (ttm)

    -151.79%

  • Revenue (ttm)

    28.86M

  • Net Income Avi to Common (ttm)

    -90.25M

  • Diluted EPS (ttm)

    -2.5600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.43M

  • Total Debt/Equity (mrq)

    79.25%

  • Levered Free Cash Flow (ttm)

    -105.47M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: